Daily Dosing of Atogepant for Preventive Treatment of Migraine Improved Patient-Reported Outcomes Measures of Activity Impairment in Migraine-Diary, Migraine-Specific Quality of Life, and Headache Impact Test in a 52-Week Trial

The requested reference [b36aa6b67cfa58ea371dff217cbcd6291b1bd394] no longer exists in our database. It has been replaced by the current reference: [fdb7cb983959af102d3e581b85199ac60ae649dd]

Authors
Category Primary study
ConferenceJournal of Headache and Pain
Year 2021
This article has no abstract
Epistemonikos ID: 76df125e8697cbb2a946f529c6bce41c997a53bb
First added on: Apr 30, 2026